Teva Pharma (TEVA) Misses Q4 EPS by 1c, FY Guidance Misses

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.53, $0.01 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $4.6 billion versus the consensus estimate of $4.52 billion.

GUIDANCE:

Teva Pharma sees FY2019 EPS of $2.20-$2.50, versus the consensus of $2.81. Teva Pharma sees FY2019 revenue of $17-17.4 billion, versus the consensus of $17.93 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity